Photo: Depositphotos
Jul 21, 2025, 16:54
Minhua Chu: Suzhou Ribo Life Science Announced the Successful Completion of its Series E Financing Round
Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Suzhou Ribo Life Science announced the successful completion of its Series E financing round, raising over RMB 200 million (approximately $28 million). The round was led by Mingxin Capital.
Ribo is a biotech focus on siRNA therapies with R&D centers in Suzhou, Beijing (China) and Gothenburg (Europe).
Pipeline.”
More post featuring Minhua Chu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 13, 2025, 14:38
Aug 13, 2025, 14:34
Aug 13, 2025, 14:30
Aug 13, 2025, 14:19